Skip to main content

and
  1. Article

    Open Access

    A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma

    Cancer vaccines as immunotherapy for solid tumours are currently in development with promising results. We report a phase 1 study of Ad-sig-hMUC1/ecdCD40L (NCT02140996), an adenoviral-vector vaccine encoding t...

    Tira J. Tan, W. X. Gladys Ang, Who-Whong Wang, Hui-Shan Chong in Nature Communications (2022)